Cardiovascular Drugs and Therapy 2009-06-01

Pharmacological approaches to modifying HDL: more basic science to understand HDL metabolism is necessary. Editorial to: "NO-1886 up-regulates Niemann-Pick C1 protein (NPC1) expression through liver X receptor alpha signaling pathway in THP-1 macrophage-derived foam cells" by Xin Ma et al.

Michael H Davidson

Index: Cardiovasc. Drugs Ther. 23(3) , 187-8, (2009)

Full Text: HTML

Structure	Name/CAS No.	Molecular Formula	Articles
	Ibrolipim CAS:133208-93-2	C₁₉H₂₀BrN₂O₄P

Effects of NO-1886 on inflammation-associated cytokines in h...
2006-07-01
[Eur. J. Pharmacol. 540(1-3) , 139-46, (2006)]

NO-1886 suppresses diet-induced insulin resistance and chole...
2010-01-01
[J. Endocrinol. 1st ed., 204 , 47-56, (2010)]

Evaluation of induction potency of new drug candidates on CY...
2009-01-01
[Drug Metab. Pharmacokinet. 24(5) , 446-50, (2009)]

NO-1886 (ibrolipim), a lipoprotein lipase-promoting agent, a...
2006-02-01
[Metab. Clin. Exp. 55(2) , 151-8, (2006)]

NO-1886, a lipoprotein lipase activator, attenuates vascular...
2007-01-12
[Eur. J. Pharmacol. 554(2-3) , 183-90, (2007)]